Anandamide

Fascinating biology but impractical as an oral supplement due to rapid enzymatic degradation by FAAH. Indirect approaches (PEA, FAAH inhibitors) are more viable.

A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.

Endogenous anandamide research is extensive, but exogenous oral supplementation data are essentially absent. FAAH rapidly degrades it in the gut and liver.

• Key signalling molecule in the endocannabinoid system
• Involved in mood regulation and pain perception
• Conceptual target for well-being research

No established supplemental dose. Oral bioavailability is negligible without advanced delivery systems.

• Unknown at supplemental doses
• Theoretical CB1-related effects if bioavailability were achieved

Products claiming oral anandamide benefits lack pharmacokinetic support. Regulatory status is ambiguous.

The compound's biology is real but oral supplementation does not meaningfully raise systemic levels.

• Mood15
• Pain15